EU regulator supports a label expansion of Novo Nordisk’s diabetes drug to reflect its potential to lower the risk of ...

Novo Nordisk (NVO) announced Saturday that its pending acquisition of three Catalent (NYSE:CTLT) production sites is expected ...

NVO's CagriSema target of up to 25% in long-term weight loss is highly promising vs. 15% through Wegovy and 20% through ...

Novo Nordisk's Ozempic will become the first and only GLP-1 drug to be shown to reduce progression of kidney disease in ...

FTC approves Novo Holdings' $16.5B Catalent acquisition. Deal includes selling 3 facilities to Novo Nordisk for $11B, despite ...

GLP-1 agonists have taken the pharma world by storm, and Novo Nordisk has been at the forefront of it all thanks to ...

Novo Nordisk announced on Thursday that a key European Medicines Agency committee has backed a label update for weight-loss ...

Novo Holdings has received the green light for its giant acquisition of the American pharmaceutical manufacturer Catalent, Ritzau reports.According to a stock exchange announcement, all regulatory ...

Danish drug maker Novo Nordisk said on Thursday it will reduce the U.S. list prices of two insulin products by more than 70% ...

Wegovy and other GLP-1 medications have become extremely popular over the past few years. Novo Nordisk (which makes both ...

We recently published a list of 12 Most Profitable Pharmaceutical Stocks Right Now. In this article, we are going to take a ...

Eli Lilly's popular weight-loss drug Zepbound outperformed Danish drugmaker Novo Nordisk's Wegovy in a clinical trial, ...